Diamedica Therapeutics Stock Earnings Reports

DiaMedica provided updates across its DM199 programs and financials. Key clinical points: ReMEDy2 (acute ischemic stroke) enrollment has surpassed ~70% with ~70 sites active globally; management reiterates intent to complete the interim analysis by the end of 2026 (futility check with potential sample size re-estimation to 300–700 patients if positive). The company expects that, if the interim supports efficacy comparable to Phase II, full enrollment could be completed in Q1 2027. Preeclampsia program: Part 1a extension cohort (late-onset preeclampsia) is near completion and a data update is expected later this quarter; Part 1b (late-onset expansion) and Part 2 (early-onset cohort) are planned to start this summer, with parallel global Phase II activity advancing in Canada (Health Canada approval received) and planned U.K. filings. The U.S. IND is delayed pending additional nonclinical reproductive/toxicity data after an adverse immune response in a rabbit study; the company has proposed performing the requested study in a second rodent model and is awaiting FDA feedback while proceeding in Canada/UK. Financials: cash, cash equivalents and short-term investments were $51.3M as of 3/31/26, with a cash burn (net cash used in operations) of $9.1M in Q1 2026; management expects current cash to fund operations through 2027. R&D spend rose (driven by ReMEDy2 global expansion and additional reproductive testing); G&A is stable. Key risks and near-term catalysts: FDA response on animal study and U.S. IND path, interim stroke analysis result (could trigger stop for futility or sample-size adjustment), upcoming preeclampsia extension cohort data this quarter, and multiple clinical milestones through end of 2027.